These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
425 related articles for article (PubMed ID: 16960863)
21. Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study. Wong GK; Wong R; Mok V; Wong A; Fan D; Leung G; Chan A; Poon WS J Clin Pharm Ther; 2009 Dec; 34(6):657-63. PubMed ID: 20175798 [TBL] [Abstract][Full Text] [Related]
22. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484 [TBL] [Abstract][Full Text] [Related]
24. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747 [TBL] [Abstract][Full Text] [Related]
25. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease. Grossberg GT; Olin JT; Somogyi M; Meng X Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961 [TBL] [Abstract][Full Text] [Related]
26. Cholinesterase inhibitors for Parkinson's disease dementia. Maidment I; Fox C; Boustani M Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494 [TBL] [Abstract][Full Text] [Related]
27. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A; Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Burns A; Spiegel R; Quarg P Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039 [TBL] [Abstract][Full Text] [Related]
35. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Bullock R; Cameron A Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787 [TBL] [Abstract][Full Text] [Related]
36. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study. Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137 [TBL] [Abstract][Full Text] [Related]
37. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. Emre M; Cummings JL; Lane RM J Alzheimers Dis; 2007 Jul; 11(4):509-19. PubMed ID: 17656830 [TBL] [Abstract][Full Text] [Related]
38. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895 [TBL] [Abstract][Full Text] [Related]
39. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Ballard C; Lane R; Barone P; Ferrara R; Tekin S Int J Clin Pract; 2006 Jun; 60(6):639-45. PubMed ID: 16805745 [TBL] [Abstract][Full Text] [Related]
40. Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Silver JM; Koumaras B; Chen M; Mirski D; Potkin SG; Reyes P; Warden D; Harvey PD; Arciniegas D; Katz DI; Gunay I Neurology; 2006 Sep; 67(5):748-55. PubMed ID: 16966534 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]